This technical application poster, originally showcased at ISCT 2024, shares data demonstrating that SOLUPORE® technology, a non-viral system and novel transfection platform, efficiently produces single and multi-gene edited induced pluripotent stem cells (iPSCs). iPSCs hold therapeutic potential due to their ability to differentiate into various cell types and this application is further enhanced by gene editing. Existing delivery methods for gene editing tools encounter challenges, such as excess cargo load and prolonged timelines for multi-step editing.

OmniaBio-CCRM has developed a robust GMP gene editing and cell line derivation pipeline for iPSCs. In collaboration with Avectas, CCRM, and OmniaBio Inc., SOLUPORE® was employed to generate single and multi-gene edited iPSCs. This poster shows the multiplex capabilities of SOLUPORE® combined with the ability to deliver sequentially, enabling diverse cargo delivery options, including knockout (KO) and knock-in (KI) editing, while maintaining cell health and reducing cell derivation workflow.

Download this poster to learn more about our GMP gene editing and cell line derivation capabilities and how SOLUPORE® efficiently produces single and multi-gene edited iPSCs.

About OmniaBio
As a dedicated cell and gene therapy CDMO, OmniaBio's vision is to manufacture a disease-free future. Headquartered in Ontario, Canada, our core values of collaborative partnership converge with deep industry experience and innovation using the latest technologies to drive the future of cell and gene therapy manufacturing.